Physician profile
Todd E Schneiderman
NPI 1033141007
$200,325.03
in general payments reported to CMS, 2019-2025
17 companies · $44K in 2025
The $44K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $139 · 2021: $1,027 · 2022: $24K · 2023: $62K · 2024: $17K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $75K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $21K · Honoraria: $11K · Travel and Lodging: $8,409 · Consulting Fee: $5,641 · Food and Beverage: $2,634 · Education: $20.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $74,988.58 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $20,598.50 |
| Honoraria | $10,789.50 |
| Travel and Lodging | $8,409.37 |
| Consulting Fee | $5,640.50 |
| Food and Beverage | $2,634.07 |
| Education | $20.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $59,272.16 | 2019-2025 | Vabysmo, Lucentis |
| Apellis Pharmaceuticals, INC. | $50,743.03 | 2022-2025 | Syfovre, Syfovre |
| Regeneron Healthcare Solutions, INC. | $31,380.22 | 2019-2025 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $28,475.11 | 2019 | |
| Coherus Oncology, INC. | $13,796.76 | 2022-2023 | |
| Genentech, INC. | $7,279.24 | 2019 | |
| Janssen Research & Development, LLC | $5,286.61 | 2022 | |
| Astellas Pharma US INC | $2,382.00 | 2024 | Izervay |
| Allergan, INC. | $940.31 | 2019-2021 | |
| Alcon Vision LLC | $150.00 | 2025 | Clareon |
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Dutch Ophthalmic, USA | $139.34 | 2021-2025 | Tissueblue, Eva, Combined Machine |
| Alimera Sciences, INC. | $89.65 | 2022-2023 | Iluvien |
| Topcon Healthcare, INC. | $89.07 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $59.69 | 2023 | Eylea |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $48.84 | 2022-2023 | |
| Eyepoint US, INC. | $43.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Schneiderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.